DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

Medtronic (NYSE:MDT) is currently navigating a landscape marked by both promising innovations and significant challenges.

Senseonics, a medtech manufacturer developing long-term, implantable continuous glucose monitoring (CGM) systems, and ...

Medtronic hasn't been growing its sales at an impressive clip of late. However, one of the company's segments looks increasingly promising. Medtronic has other growth opportunities and is a solid ...

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

There is even more good news for Medtronic. The company recently earned U.S. clearance for a continuous glucose monitoring (CGM) system called Simplera. It also announced a partnership with Abbott ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

Medtronic may be an underrated beneficiary of declining interest rates. That's because as rates come down, it becomes less ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...

Medtronic faced challenges ... insulin delivery with no pumps or needles and continuous glucose monitoring (“CGM”), impacted sales. The firm's recent product approval of the MiniMed 780G ...